Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Poll|October 26, 2015
Mini Quiz: Violence and Psychosis
What percentage of patients hospitalized for a first episode of schizophrenia who had threatened others had displayed overt signs of illness for over a year?
Advertisement
Findings indicate that more than ____% of patients hospitalized for a first episode of schizophrenia who had threatened others had displayed overt signs of illness for over a year.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Don't miss out on these CME articles! Test your knowledge here.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
What Clinicians Need to Know About Postpartum Psychosis
3
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5